Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease

Neurobiology of Disease

Volumn 14, Issue 3, 2003, Pages 404-416

  Calon, Frédéric ^d   Rajput, Ali H ^a   Hornykiewicz, Oleh ^a,b   Bédard, Paul J ^d   Di Paolo, Thérèse ^c  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF VIENNA   (Austria)

^c LAVAL UNIVERSITY   (Canada)

^d NONE

Author keywords

AMPA; Autoradiography; CGP39653; Dyskinesia; In situ hybridization; NMDA; NR1; Ro 25 6981; Wearing off

Indexed keywords

2 AMINO 4 PHOSPHONOMETHYL 3 HEPTENOIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TRITIUM;

ARTICLE; AUTONOMIC DENERVATION; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG BINDING; DYSKINESIA; HUMAN; IN SITU HYBRIDIZATION; LONG TERM CARE; MOTOR DEVELOPMENT; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUTAMEN; RECEPTOR SENSITIVITY; SUPERSENSITIVITY;

EID: 0346218258     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2003.07.003     Document Type: Article

References (87)

1. Anglade P., Mouatt-Prigent A., Agid Y., Hirsch E. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration. 5:1996;121-128.
2. Aubert I., Ghorayeb I., Normand E., Bloch B. Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum. J. Comp. Neurol. 418:2000;22-32.
3. Ball E.F., Shaw P.J., Ince P.G., Johnson M. The distribution of excitatory amino acid receptors in the normal human midbrain and basal ganglia with implications for Parkinson's disease a quantitative autoradiographic study using [3H] MK-801, [3H] glycine, [3H] CNOX and [3H] kainate . Brain Res. 658:1994;209-218.
4. Benabid A.L., Benazzouz A., Limousin P., Koudsie A., Krack P., Piallat B., Pollak P. Dyskinesias and the subthalamic nucleus. Ann. Neurol. 47:2000;S189-S192.
5. Bernard V., Gardiol A., Faucheux B., Bloch B., Agid Y., Hirsch E.C. Expression of glutamate receptors in the human and rat basal ganglia effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion . J. Comp. Neurol. 368:1996;553-568.
6. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 290:1999;1034-1040.
7. Blanchet P.J., Metman L.V., Mouradian M.M., Chase T.N. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov. Disord. 11:1996;580-581.
8. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 21:1997;447-453.
9. Bravi D., Mouradian M.M., Roberts J.W., Davis T.L., Sohn Y.H., Chase T.N. Wearing-off fluctuations in Parkinson's disease contribution of postsynaptic mechanisms . Ann. Neurol. 36:1994;27-31.
10. Brotchie J.M. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann. Neurol. 47:2000;S105-S112. discussion S112-S104.
11. Calabresi P., Giacomini P., Centonze D., Bernardi G. Levodopa-induced dyskinesia a pathological form of striatal synaptic plasticity . Ann. Neurol. 47:2000;S60-S68.
12. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain. 116:1993;433-452.
13. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskine. J. Neuropathol. Exp. Neurol. 61:2002;186-196.
14. Calon F., Grondin R., Morissette M., Goulet M., Blanchet P.J., Di Paolo T., Bedard P.J. Molecular basis of levodopa-induced dyskinesias. Ann. Neurol. 47:2000;S70-S78.
15. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., Di Paolo T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 26:2002;127-138.
16. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 18:2003;241-253.
17. Cepeda C., Buchwald N.A., Levine M.S. Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc. Natl. Acad. Sci. USA. 90:1993;9576-9580.
18. Chase T.N., Oh J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. 47:2000;S122-S129.
19. Chen Q., Reiner A. Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res. 743:1996;346-352.
20. de la Fuente-Fernandez R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., Lee C.S., Ruth T.J., Calne D.B., Stoessl A.J. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease PET evidence of increased dopamine turnover . Ann. Neurol. 49:2001;298-303.
21. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol. Rev. 51:1999;7-61.
22. Di Paolo T., Bedard P., Daigle M., Boucher R. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys. Brain Res. 379:1986;286-293.
23. Dunah A.W., Standaert D.G. Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane. J. Neurosci. 21:2001;5546-5558.
24. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 57:2000;342-352.
25. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport. 5:1994;2586-2588.
26. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 47:2000;S2-S9.
27. Fischer G., Mutel V., Trube G., Malherbe P., Kew J.N., Mohacsi E., Heitz M.P., Kemp J.A. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther. 283:1997;1285-1292.
28. Freund T.F., Powell J.F., Smith A.D. Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience. 13:1984;1189-1215.
29. Gerlach M., Gsell W., Kornhuber J., Jellinger K., Krieger V., Pantucek F., Vock R., Riederer P. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia- thalamocortical circuits in Parkinson syndrome. Brain Res. 741:1996;142-152.
30. Greenamyre J.T. Glutamatergic influences on the basal ganglia. Clin. Neuropharmacol. 24:2001;65-70.
31. Hadj Tahar, A., Gregoire, L., Darre, A., Belanger, N., Meltzer, L., Bedard, P.J., 2001. Prevention of L-Dopa-induced dyskinesias by a selective NR1A/2B NMDA receptor antagonist in parkinsonian monkeys, in: Society of Neuroscience Abstracts, Vol. 27, Program No 200.7, San Diego.
32. He L., Di Monte D.A., Langston J.W., Quik M. Autoradiographic analysis of N-methyl-D-aspartate receptor binding in monkey brain effects of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine and levodopa treatment . Neuroscience. 99:2000;697-704.
33. Healy D.J., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J., Meador-Woodruff J.H. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology. 19:1998;278-286.
34. 3H] MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy. Brain Res. 565:1991;154-157.
35. Jaarsma D., Sebens J.B., Korf J. Glutamate dehydrogenase improves binding of [3H] CGP39653 to NMDA receptors in the autoradiographic assay. J. Neurosci. Methods. 46:1993;133-138.
36. Kingsbury A.E., Foster O.J., Nisbet A.P., Cairns N., Bray L., Eve D.J., Lees A.J., Marsden C.D. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Mol. Brain Res. 28:1995;311-318.
37. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology. 54:2000;1589-1595.
38. Kosinski C.M., Standaert D.G., Counihan T.J., Scherzer C.R., Kerner J.A., Daggett L.P., Velicelebi G., Penney J.B., Young A.B., Landwehrmeyer G.B. Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain striatum and globus pallidus . J. Comp. Neurol. 390:1998;63-74.
39. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44:1994;163-196.
40. Lange K.W., Kornhuber J., Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci. Biobehav. Rev. 21:1997;393-400.
41. Laurie D.J., Seeburg P.H. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition. Eur. J. Pharmacol. 268:1994;335-345.
42. Levey A.I., Hersch S.M., Rye D.B., Sunahara R.K., Niznik H.B., Kitt C.A., Price D.L., Maggio R., Brann M.R., Ciliax B.J., et al. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc. Natl. Acad. Sci. USA. 90:1993;8861-8865.
43. Lopez A., Munoz A., Guerra M.J., Labandeira-Garcia J.L. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience. 103:2001;639-651.
44. Luginger E., Wenning G.K., Bosch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 15:2000;873-878.
45. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease clinical and pharmacological classification . Mov. Disord. 7:1992;117-124.
46. Lynch D.R., Anegawa N.J., Verdoorn T., Pritchett D.B. N-Methyl-D-aspartate receptors different subunit requirements for binding of glutamate antagonists, glycine antagonists, and channel-blocking agents . Mol. Pharmacol. 45:1994;540-545.
47. Marconi R., Lefebvre-Caparros D., Bonnet A.M., Vidailhet M., Dubois B., Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov. Disord. 9:1994;2-12.
48. Marin C., Jimenez A., Bonastre M., Chase T.N., Tolosa E. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats. Synapse. 36:2000;267-274.
49. Marin C., Papa S., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205.
50. Markham C.H., Diamond S.G. Evidence to support early levodopa therapy in Parkinson disease. Neurology. 31:1981;125-131.
51. Mengual E., de las Heras S., Erro E., Lanciego J.L., Gimenez-Amaya J.M. Thalamic interaction between the input and the output systems of the basal ganglia. J. Chem. Neuroanat. 16:1999;187-200.
52. Meoni P., Bunnemann B.H., Kingsbury A.E., Trist D.G., Bowery N.G. NMDA NR1 subunit mRNA and glutamate NMDA-sensitive binding are differentially affected in the striatum and pre-frontal cortex of Parkinson's disease patients. Neuropharmacology. 38:1999;625-633.
53. Meshul C.K., Emre N., Nakamura C.M., Allen C., Donohue M.K., Buckman J.F. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience. 88:1999;1-16.
54. Michaelis E.K. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog. Neurobiol. 54:1998;369-415.
55. Montastruc J.L., Rascol O., Senard J.M. Glutamate antagonists and Parkinson's disease a review of clinical data . Neurosci. Biobehav. Rev. 21:1997;477-480.
56. 3H] Ro 25-6981, a potent and selective antagonist of NMDA receptors containing NR2B subunits. J. Neurochem. 70:1998;2147-2155.
57. Nash J.E., Brotchie J.M. A common signaling pathway for striatal NMDA and adenosine A2a receptors implications for the treatment of Parkinson's disease . J. Neurosci. 20:2000;7782-7789.
58. Nutt J.G. Levodopa-induced dyskinesia review, observations, and speculations . Neurology. 40:1990;340-345.
59. Nutt J.G., Obeso J.A., Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci. 23:2000;S109-S115.
60. Obeso J.A., Rodriguez-Oroz M.C., Chana P., Lera G., Rodriguez M., Olanow C.W. The evolution and origin of motor complications in Parkinson's disease. Neurology. 55:2000;S13-20.
61. Oh J.D., Russell D., Vaughan C.L., Chase T.N. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits effect of dopaminergic denervation and L-DOPA administration . Brain Res. 813:1998;150-159.
62. Oh J.D., Vaughan C.L., Chase T.N. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Brain Res. 821:1999;433-442.
63. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:1995;13-18.
64. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
65. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Rev. 20:1995;91-127.
66. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Rev. 20:1995;128-154.
67. Parent A., Sato F., Wu Y., Gauthier J., Levesque M., Parent M. Organization of the basal ganglia the importance of axonal collateralization . Trends Neurosci. 23:2000;S20-S27.
68. Planells-Cases R., Sun W., Ferrer-Montiel A.V., Montal M. Molecular cloning, functional expression, and pharmacological characterization of an N-methyl-D-aspartate receptor subunit from human brain. Proc. Natl. Acad. Sci. USA. 90:1993;5057-5061.
69. Ponte P., Ng S.Y., Engel J., Gunning P., Kedes L. Evolutionary conservation in the untranslated regions of actin mRNAs DNA sequence of a human beta-actin cDNA . Nucleic Acids Res. 12:1984;1687-1696.
70. Rajput A.H., Fenton M.E., Birdi S., Macaulay R., George D., Rozdilsky B., Ang L.C., Senthilselvan A., Hornykiewicz O. Clinical-pathological study of levodopa complications. Mov. Disord. 17:2002;289-296.
71. Rajput A.H., Rajput A., Lang A.E., Kumar R., Uitti R.J., Galvez-Jimenez N. New use for an old drug amantadine benefits levodopa-induced dyskinesia . Mov. Disord. 13:1998;851.
72. Ruzicka E., Streitova H., Jech R., Kanovsky P., Roth J., Rektorova I., Mecir P., Hortova H., Bares M., Hejdukova B., Rektor I. Amantadine infusion in treatment of motor fluctuations and dyskinesias in Parkinson's disease. J. Neural Transm. 107:2000;1297-1306.
73. Shoulson I. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology. 56:2001;455-462.
74. Silverdale M.A., Crossman A.R., Brotchie J.M. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Exp. Neurol. 174:2002;21-28.
75. Smith Y., Bennett B.D., Bolam J.P., Parent A., Sadikot A.F. Synaptic relationships between dopaminergic afferents and cortical or thalamic input in the sensorimotor territory of the striatum in monkey. J. Comp. Neurol. 344:1994;1-19.
76. Smith Y., Bevan M.D., Shink E., Bolam J.P. Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience. 86:1998;353-387.
77. Snow B.J., Macdonald L., McAuley D., Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease a double-blind, placebo-controlled study . Clin. Neuropharmacol. 23:2000;82-85.
78. 125I] RTI-121. Synapse. 21:1995;364-372.
79. Tossman U., Segovia J., Ungerstedt U. Extracellular levels of amino acids in striatum and globus pallidus of 6-hydroxydopamine-lesioned rats measured with microdialysis. Acta Physiol. Scand. 127:1986;547-551.
80. Ulas J., Weihmuller F.B., Brunner L.C., Joyce J.N., Marshall J.F., Cotman C.W. Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson's disease, Alzheimer's disease, and mixed Parkinson's disease/Alzheimer's disease patients an autoradiographic study . J. Neurosci. 14:1994;6317-6324.
81. Verhagen Metman L., Del Dotto P., LePoole K., Konitsiotis S., Fang J., Chase T.N. Amantadine for levodopa-induced dyskinesias a 1-year follow-up study . Arch. Neurol. 56:1999;1383-1386.
82. Verhagen Metman L., Del Dotto P., Natte R., van den Munckhof P., Chase T.N. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology. 51:1998;203-206.
83. Verhagen Metman L., Konitsiotis S., Chase T.N. Pathophysiology of motor response complications in Parkinson's disease hypotheses on the why, where, and what . Mov. Disord. 15:2000;3-8.
84. Verhagen Metman L., Morris M.J., Farmer C., Gillespie M., Mosby K., Wuu J., Chase T.N. Huntington's disease a randomized, controlled trial using the NMDA-antagonist amantadine . Neurology. 59:2002;694-699.
85. Weihmuller F.B., Ulas J., Nguyen L., Cotman C.W., Marshall J.F. Elevated NMDA receptors in parkinsonian striatum. NeuroReport. 3:1992;977-980.
86. Wisden, W., Morris, B.J., 1994. In situ hybridization with synthetic oligonucleotide probes, in: Wisden, W., Morris, B.J. (Eds.), In Situ Hybridization Protocols for the Brain, Academic Press, San Diego, pp. 9-34.
87. Zilles K., Qu M.S., Kohling R., Speckmann E.J. Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue quantitative in vitro receptor autoradiography . Neuroscience. 94:1999;1051-1061.